This page compares ibogaine and naltrexone across the criteria that matter most for opioid use disorder (OUD) treatment: how each works, what the research shows, what risks are involved, and who each option may suit best.

At a Glance

Criterion Ibogaine Naltrexone
Mechanism Multi-target psychedelic; resets opioid receptors, modulates dopamine/serotonin/NMDA systems Opioid antagonist; blocks mu-opioid receptors, removes reward response
Evidence Level Observational studies, case series; no Phase III RCTs Multiple RCTs; FDA-approved (oral and extended-release injectable)
Treatment Duration 1–3 sessions over days; effects may persist months Daily oral pill or monthly injection; ongoing maintenance
Legal Status (US) Schedule I controlled substance FDA-approved; Schedule not applicable
Access Clinics in Mexico, Canada, Portugal, NZ; limited legal US trials Widely available via physicians, addiction clinics, telehealth
Typical Cost $5,000–$15,000+ per treatment episode $50–$150/month oral; ~$1,500/month injectable (Vivitrol); often insured
Key Risks Cardiac arrhythmia, QT prolongation, fatalities; intense psychedelic experience Precipitates withdrawal if opioids present; overdose risk if discontinued; hepatotoxicity at high doses
Best Studied For Opioid detoxification, reducing withdrawal, craving interruption Relapse prevention in abstinent patients; alcohol use disorder (dual diagnosis)

Mechanism of Action

Naltrexone works through a straightforward competitive mechanism: it binds with high affinity to mu-opioid receptors and blocks them, meaning opioids taken while naltrexone is active produce little to no euphoria. Extended-release injectable naltrexone (XR-NTX, brand name Vivitrol) maintains this blockade continuously for approximately 30 days, removing the daily adherence burden. The drug does not itself produce euphoria, is not considered habit-forming, and leaves no physical dependence on discontinuation.

Ibogaine's pharmacology is substantially more complex. It acts on multiple neurological systems simultaneously: it is an NMDA receptor antagonist, a kappa- and mu-opioid receptor ligand, a serotonin reuptake inhibitor, and an acetylcholinesterase inhibitor. Its primary active metabolite, noribogaine, has a much longer half-life (up to 72 hours) and is thought to play a central role in the sustained anti-addictive effects observed clinically. Researchers hypothesize that this multi-target activity produces a rapid "resetting" of dysregulated reward circuitry, which may explain why some patients report dramatically reduced cravings after a single session. The mechanism is not yet fully characterized.

Clinical Evidence

Naltrexone's evidence base is extensive and well-established. Oral naltrexone has been FDA-approved for opioid use disorder since 1984. Extended-release injectable naltrexone received approval in 2010, supported by a landmark randomized controlled trial (Krupitsky et al., 2011) showing significantly higher abstinence rates versus placebo at six months. A major comparative effectiveness trial (X:BOT, Lee et al., 2018) found XR-NTX equivalent to buprenorphine-naloxone in outcomes among patients who successfully initiated treatment, though the induction hurdle — requiring full opioid detoxification before starting — was a significant barrier, with more XR-NTX patients failing to initiate.

Ibogaine's clinical evidence remains at an earlier stage. There are no completed Phase III randomized controlled trials. Evidence comes primarily from observational studies, case series, and prospective cohort studies. A widely cited 2017 study by Brown & Alper examined 191 patients treated at a Mexican clinic and found significant reductions in opioid withdrawal severity and sustained reductions in opioid use at one-month follow-up. A 2021 retrospective study of military veterans (Noller et al.) reported reductions in PTSD, depression, and substance use at 12 months. Stanford's 2023 observational study of 30 Special Operations veterans found improvements in cognitive function, mental health, and disability, though this focused on TBI rather than OUD specifically. New Zealand has conducted the most formal government-supported ibogaine research; Phase II trials are ongoing. MAPS and other organizations are pursuing IND approvals in the US. The current evidence is promising but insufficient by conventional pharmaceutical standards.

Safety Profile

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision and pre-treatment cardiac screening required.

Ibogaine's most serious risk is cardiac toxicity. It prolongs the QT interval on an electrocardiogram, which can precipitate life-threatening ventricular arrhythmias including torsades de pointes. A review of ibogaine-associated fatalities identified cardiac events as a leading cause of death, often in patients with pre-existing but undiagnosed cardiac conditions or those who used opioids concurrently during treatment. Responsible clinics currently require a 12-lead ECG, cardiac history review, and in some cases cardiology consultation before treatment. Ibogaine also produces an intense, extended psychedelic experience (typically 18–36 hours) that can be psychologically challenging and requires experienced supervision. It is contraindicated in patients with certain cardiac conditions, psychiatric history of psychosis, and several medication classes.

Naltrexone's safety profile is considerably better established. Its most clinically significant risk is precipitated opioid withdrawal: administering naltrexone to a patient with any opioid physical dependence triggers severe, immediate withdrawal. For this reason, patients must be fully detoxified — typically 7–10 days opioid-free for most opioids, longer for methadone — before induction. This detoxification period itself carries risk, as tolerance drops and patients who relapse before restarting treatment are at elevated overdose risk. Naltrexone at standard doses is generally well tolerated; high-dose use has been associated with hepatotoxicity, though this is rarely clinically significant at approved doses. A major indirect safety concern is that patients who stop XR-NTX between doses have reduced opioid tolerance and face elevated overdose risk if they relapse.

Cost and Access

Naltrexone is among the most accessible OUD treatments currently available. Oral naltrexone is inexpensive and available generically. XR-NTX (Vivitrol) is more costly but is covered by most state Medicaid programs, many private insurers, and the VA. It can be prescribed by any licensed physician — no special waiver is currently required — and is increasingly available through telehealth platforms, emergency departments, and primary care settings.

Ibogaine access involves logistical, financial, and legal barriers that significantly limit its availability. In the United States, ibogaine is a Schedule I controlled substance, making its administration outside of a federally approved research context illegal. Patients seeking ibogaine treatment currently travel primarily to clinics in Mexico (the largest concentration), Portugal, the Netherlands, Canada, and New Zealand. Treatment costs at established medical clinics typically range from $5,000 to $15,000 or more per episode, covering the multi-day supervised protocol, medical monitoring, and facility costs. This cost is almost never covered by insurance. Ongoing US legislative efforts — including state-level decriminalization measures and federal research bills — may expand legal access over the coming years, but ibogaine remains difficult to access for the majority of OUD patients.

Who Each Treatment May Suit

Naltrexone is generally considered for patients who have completed opioid detoxification, are motivated toward full abstinence, have stable social support, and can adhere to a medication regimen — or who prefer the once-monthly injection format to remove the daily decision to take a pill. It is also a strong option for patients with concurrent alcohol use disorder, since naltrexone is FDA-approved for both conditions. It is not appropriate for patients who are currently physically dependent on opioids, those who require ongoing opioid pain management, or those unable to complete detoxification.

Ibogaine is most commonly sought by patients who have failed multiple prior treatment attempts with standard therapies, who want a rapid interruption of both physical withdrawal symptoms and psychological craving patterns, or who are motivated to address underlying psychological contributors to addiction in a condensed intensive format. Many candidates are adults in relatively good physical health without cardiac contraindications who can afford and travel to an international clinic. It is not appropriate for patients with cardiac conditions, a personal or family history of QT prolongation, active psychosis, or several medication contraindications including certain antidepressants and antiarrhythmics.

Key Difference

The most fundamental distinction between ibogaine and naltrexone is the stage of OUD they are designed to address and the model of care each represents. Naltrexone is a maintenance medication with a strong evidence base, designed for long-term relapse prevention in patients already abstinent from opioids — its effectiveness depends heavily on sustained adherence. Ibogaine is positioned as an intensive, episodic intervention aimed at rapidly interrupting physical dependence and craving through a neurobiologically complex mechanism, with some patients reporting sustained benefits after a single treatment; however, its evidence remains observational, its risks are substantially greater, and its access is severely restricted. These differences mean the two treatments occupy largely distinct — though occasionally overlapping — positions in the OUD treatment landscape.

Frequently Asked Questions

Some ibogaine clinics incorporate naltrexone — often extended-release injectable naltrexone — as a follow-up protocol after ibogaine treatment to support continued abstinence during the post-treatment window. Because ibogaine itself clears mu-opioid receptor binding and reduces cravings, the combination of acute ibogaine detoxification followed by XR-NTX maintenance is a clinically logical sequence used at some facilities. However, ibogaine and naltrexone must never be administered simultaneously or in close proximity without expert medical oversight, as their interaction profiles are not fully studied. Naltrexone should not be started until ibogaine and noribogaine have cleared the system, which may take several days to over a week.
No — naltrexone does not treat opioid withdrawal and will make it dramatically worse if administered to someone physically dependent on opioids. It precipitates severe, immediate withdrawal in dependent patients. Naltrexone is indicated only after full detoxification is complete. Some rapid or ultra-rapid detoxification protocols use anesthesia or sedation to manage precipitated withdrawal during naltrexone induction, but these approaches carry their own risks and are not standard of care. Ibogaine, by contrast, is specifically noted in research for its ability to rapidly suppress opioid withdrawal symptoms during the acute treatment window.
Methadone and buprenorphine are opioid agonist therapies (OAT) — they act on opioid receptors to prevent withdrawal and cravings through a substitution model, and are considered the gold standard of OUD pharmacotherapy based on the strongest evidence base of any OUD treatments, including large reductions in overdose mortality. Ibogaine is not an opioid agonist and is not intended for ongoing maintenance in the same way. Ibogaine is typically sought by patients who have not succeeded with or do not want agonist-based therapy. Comparing ibogaine to OAT is difficult because they are used at different stages, have different goals, and have vastly different evidence bases — OAT has decades of RCT and real-world data demonstrating mortality reduction; ibogaine does not yet have this level of evidence.
Reputable ibogaine clinics currently require at minimum a 12-lead ECG to assess baseline QTc interval — a QTc above approximately 450–470 ms is typically a contraindication. Many clinics also require a complete metabolic panel, liver function tests, and a detailed cardiac history. Some require an echocardiogram or formal cardiology clearance for patients over a certain age or with any cardiac risk factors. Medications that independently prolong the QT interval — including many antidepressants, antipsychotics, and antibiotics — must be disclosed and may require washout periods. Patients should verify that any clinic they consider has a formal medical screening protocol; treatment at facilities without rigorous screening represents a significantly higher safety risk.
Adherence is naltrexone's most significant practical challenge, particularly with the daily oral formulation. Clinical trials and real-world data consistently show that discontinuation rates for oral naltrexone are high, and effectiveness drops sharply when patients stop taking it. Extended-release injectable naltrexone addresses the daily adherence issue by providing continuous coverage for approximately 30 days per injection, which research suggests improves outcomes. However, patients still need to return for monthly injections and must remain motivated to do so. Patients who have low motivation or inadequate social support may have better outcomes with opioid agonist therapy, which has demonstrated effectiveness across a broader spectrum of patient motivation levels.
Currently, ibogaine can only be legally administered in the US within the context of an FDA-approved clinical trial under an Investigational New Drug (IND) exemption. A small number of research sites are conducting or recruiting for such trials. Outside of these trials, ibogaine treatment for OUD is not legally available domestically. Several US states have introduced or passed measures related to psychedelic decriminalization or research access, but none currently create a legal treatment pathway for ibogaine specifically. Federal legislation to expand ibogaine research access has been introduced in Congress. The most common legal option for US patients remains traveling to licensed clinics in Mexico, Portugal, Canada, or New Zealand, where ibogaine treatment operates legally under each country's respective regulations.
Naltrexone's duration depends entirely on the formulation: oral naltrexone must be taken daily to maintain opioid receptor blockade, while XR-NTX provides approximately 30 days of coverage per injection. When discontinued, its effects resolve quickly, and opioid tolerance returns to pre-treatment levels, raising overdose risk. Ibogaine's active metabolite noribogaine can persist in the body for weeks after treatment, and some patients report reduced cravings and psychological shifts lasting months to over a year after a single session. However, outcomes vary significantly between individuals, and some patients require repeat treatments. Long-term follow-up data is limited, and the durability of ibogaine's effects in larger, more rigorously studied populations remains an important open research question.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.